Back
Compare AU
Compare GARP vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P World Ex Australia Garp ETF (GARP) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
GARP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 73 |
Median incremental investment | $1,018.25 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,101.13 | $1,696.50 |
Average age group | > 35 | > 35 |
Key Summary
GARP | CURE | |
|---|---|---|
Strategy | GARP.AX was created on 2024-09-24 by Global X. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the S&P World Ex-Australia GARP.AX Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Alphabet Inc Class C (6.39 %) NVIDIA Corp (6.06 %) Microsoft Corp (4.93 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Information Technology (29.10 %) Other (22.79 %) Communication Services (20.23 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0 % | 0.45 % |
Key Summary
GARP | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P World Ex-Australia GARP Index - AUD - Benchmark TR Gross | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $12.97 | $59.82 |
Size | $124.128 million | $38.099 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.09 % | 5.08 % |
Market | ASX | ASX |
First listed date | 25/09/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GARP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 73 |
Median incremental investment | $1,018.25 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,101.13 | $1,696.50 |
Average age group | > 35 | > 35 |
Pros and Cons
GARP | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GARP | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |